<DOC>
	<DOCNO>NCT01271985</DOCNO>
	<brief_summary>The purpose study determine effect PolyPill tablet ( fix dose combination two anti-hypertensive medication , atorvastatin aspirin ) primary secondary prevention cardiovascular disease Iranian adult older 50 .</brief_summary>
	<brief_title>Prevention Cardiovascular Disease Middle-aged Elderly Iranians Using Single PolyPill</brief_title>
	<detailed_description>Cardiovascular disease ( myocardial infarction stroke ) common cause death disability Iran account nearly half all-cause mortality Iranians . Therefore , prevention cardiovascular disease top priority country limit health system budget Iran . Eighty seven hundred percent patient die Coronary Heart Disease ( CHD ) least one risk factor cardiovascular disease . Therefore , risk factor modification middle-aged old individual might prevent death main priority . Combination drug therapy propose cost-effective measure reduce modifiable risk factor cardiovascular disease age people . It show combination drug therapy potentially decrease ischemic heart event stroke 88 80 percent , respectively . The purpose study determine effect PolyPill tablet ( fix dose combination two anti-hypertensive medication , atorvastatin aspirin ) primary secondary prevention cardiovascular disease Iranian adult older 50 . This study subject old 50 enrol Golestan Cohort Study . The study design pragmatic cluster randomize trial . The study comprise three arm follow : 1 . 3500 randomly select participant receive PolyPill tablet daily Minimal care ( consist direct education pamphlet cardiovascular risk reduction , biannual follow-ups BP measurement ) . 2 . 3500 randomly select participant receive Minimal care describe . 3 . 24000 participant receive usual care ( basic primary health care provide local physician Community Health Workers whole participant Golestan Cohort study consistent current Iranian Health Care System guideline ) . Arms # 1 # 2 compare via 2-armed open-labeled cluster Randomized Controlled Trial . Comparisons arm # 3 2 arm also perform . Endpoints include major cardiovascular event ( death hospitalization )</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>5079 year old Enrollment Golestan Cohort Study 1 . Hypersensitivity PolyPill component : 1 . Hypersensitivity Nonsteroidal antiinflammatory agent 2 . Hypersensitivity statins 3 . Hypersensitivity hydrochlorothiazide sulfonamides 4 . Hypersensitivity enalapril valsartan 2 . Past medical history angioedema 3 . Medical history GI bleeding peptic ulcer last 3 month 4 . Pregnancy lactation 5 . Bleeding disorder hemophilia 6 . Receiving anticoagulation therapy 7 . Alcohol consumption great 40gr/week 8 . Advanced liver disease 9 . Uncontrolled seizures 10 . Asthma follow criterion present : 1 . Daily symptoms 2 . Asthmatic attack wake patient sleep week 3 . History nasal polyps 4 . Aspirin sensitive asthma 5 . Presence rhinitis symptom due infection 11 . Past medical history gout 12 . Serum creatinine value 2 mg/dL Glomerular Filtration Rate ( GFR ) 30 mL/min 13 . Hemoglobin concentration 11 g/dL male 10 g/dL female 14 . BP &lt; 90/60 15 . Debilitating medical/mental disorder affect medication compliance ( include psychosis , disability , blindness ) 16 . Past medical history stroke</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Drug Combinations</keyword>
	<keyword>prevention control</keyword>
	<keyword>Aspirin</keyword>
	<keyword>Antihypertensive Agents</keyword>
	<keyword>Antilipemic Agents</keyword>
</DOC>